Literature DB >> 8436149

Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients.

H Lithell1, L Weiner, B Vessby, M L Nordström.   

Abstract

The effects of bisoprolol 2.5 and 5 mg per day on blood pressure, and lipoprotein and apolipoprotein concentrations were compared in 18 newly detected hypertensives in a double-blind, crossover study. All treatment results were related to the values at the end of a four-week placebo run-in period. Each of the two following treatment periods lasted for 3 months. The systolic and diastolic pressures in the supine position were reduced by 19.5/11.7 mm Hg and 14.6/10.4 mm Hg by 2.5 and 5 mg bisoprolol per day, respectively, with no significant difference in effect. Supine heart rate was reduced by 4.7 and 8.2 beats.min-1, respectively, (P = 0.0517 for different effects). The cholesterol concentration in low-density (LDL) and high-density (HDL) lipoproteins was reduced during both regimens, by about 0.3 and 0.1 mmol.l-1, respectively, difference not significant. Triglyceride concentrations were not significantly affected during either regimen. We conclude that, in this study population, treatment with bisoprolol 2.5 mg per day was equally effective as 5.0 mg per day in reducing blood pressure. The effects on lipoprotein concentrations were small and included an unexpected reduction in LDL-cholesterol concentration. A low dose of a highly selective beta-adrenoceptor blocker like bisoprolol appears to retain the blood pressure reducing capacity and has lost most of the unfavourable effects on lipoproteins characteristic of higher doses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436149     DOI: 10.1007/bf00315274

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.

Authors:  G Frithz; L Weiner
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

Review 2.  The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

3.  The triglyceride issue: a view from Framingham.

Authors:  W P Castelli
Journal:  Am Heart J       Date:  1986-08       Impact factor: 4.749

4.  Determination of the new beta-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography.

Authors:  K U Bühring; A Garbe
Journal:  J Chromatogr       Date:  1986-10-31

5.  Balanced pharmacokinetics and metabolism of bisoprolol.

Authors:  G Leopold
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

6.  High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.

Authors:  G Haeusler; H J Schliep; P Schelling; K H Becker; M Klockow; K O Minck; H J Enenkel; E Schulze; R Bergmann; C J Schmitges
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

7.  A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure.

Authors:  H Lithell; L Weiner; I Selinus; B Vessby
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

  7 in total
  3 in total

Review 1.  Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects?

Authors:  A M MacConnachie; D Maclean
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

2.  Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study.

Authors:  Yun-Dai Chen; Xin-Chun Yang; Vinh Nguyen Pham; Shi-An Huang; Guo-Sheng Fu; Xiao-Ping Chen; Binh Quang Truong; Yu Yang; Shao-Wen Liu; Tian-Rong Ma; Dong-Soo Kim; Tae-Hoon Kim
Journal:  Chin Med J (Engl)       Date:  2020-05-20       Impact factor: 2.628

3.  Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 pathway.

Authors:  Simei Sun; Hae Jin Kee; Li Jin; Yuhee Ryu; Sin Young Choi; Gwi Ran Kim; Myung Ho Jeong
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.